• Anti-aging gene therapies, non-viral approaches and disease as information with Matthew Scholz.

  • Apr 25 2024
  • Length: 1 hr and 16 mins
  • Podcast

Anti-aging gene therapies, non-viral approaches and disease as information with Matthew Scholz.

  • Summary

  • Matthew Scholz is a serial entrepreneur with a background in computer science and immunology, bridging the best of the fields of physics, computing, genetics and medicine, he is on the forefront of anti-aging technologies and non-ordinary approaches to rare disease gene therapies.


    Matt is a Chief Executive Officer and co-founder of Oisín Bio, a company focused on mitigating the senolytic technology to combat age-related diseases, With a gene delivery technology based on non-viral proteo-lipid vehicles. Matt is the founder of Immusoft, a biotech developing a breakthrough technology that turns a patient's B cells into miniature drug factories. He is a Co-Founder and Board Director of Sigma Genetics, Inc is building a non-invasive device that can deliver charged molecules, such as DNA, RNA, and proteins into patient cells. He is a CEO and Board Member, OncoSenX, Inc. (a developer of transient gene therapies designed for solid tumors). Lastly, he is a Co-Founder and Chief Technical Officer of Aegis Life, a company that works to protect human health from infectious diseases through Fusogenix technology.


    In our conversation Matt shares his fascination with programming and immunology, especially the concept of immune memory and creation of the immune software, hence, Immusoft, where B cells are reprogrammed to become enzyme producing factories. Matt discusses the MPS1 program and the work it took to dose the first patient with this detrimental disease.


    We lead the discussion into the information theory of aging, treating genetic disease as misinformation and hence, its correction. We touch on the transposon systems and the mysteries of retroviral DNA.


    We then get into viral versus non viral approaches to gene therapy. You will be delighted to learn about the progress in follistatin gene therapy for enhancing muscle growth, senolytic gene therapy to tackle age related diseases and the continuous ever changing views that FDA takes on such uncharted territories.


    We are thrilled to bring you this episode and we hope it amuses you with new and groundbreaking ideas!


    As always, nothing on this podcast should be considered a medical advice, and opinions expressed are speakers' own.


    Like and Subscribe to support us! Leave a comment with your questions and suggestions for the future episodes!

    Show more Show less

What listeners say about Anti-aging gene therapies, non-viral approaches and disease as information with Matthew Scholz.

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.